Sona completes treatment of first patient cohort in FS

Executive Summary

• Sona Nanotech Inc. has completed treatment and follow-up assessments for the first cohort of patients in its first-in-human early feasibility study of Targeted Hyperthermia (THT) therapy for late-stage melanoma.
• Treatment for the second cohort of patients has been approved, with the Chief Medical Officer overseeing further treatments in Santiago.
• The company reports no significant adverse health events in the first cohort and cites optimism based on early clinical responses and tumor biopsy results.

Key Details

• Study Status: Completed treatment and follow-up for the first cohort of the early feasibility study; second cohort treatment approved and underway.
• Location: Treatments being overseen in Santiago by Sona's Chief Medical Officer, Dr. Carman Giacomantonio.
• Safety Profile: No significant adverse health events reported in patients from the first cohort.
• Clinical Observations: Early clinical responses and tumor biopsy results from treated patients have provided "reason for optimism."
• Timeline: Targeted number of patients to be completed by the end of September.
• Next Steps: Extensive scientific analysis to assess immune engagement in treated tumors following THT.
• Regulatory Progress: Ethics approval previously secured for a larger clinical trial in Canada; current learnings from the feasibility study are being incorporated into the application to Health Canada.
• Data Publication: Additional scientific insights from studies planned for submission to leading scientific journals in the fall.

Notable Quotes

• Dr. Carman Giacomantonio, Sona CMO: "We are very pleased with the progress of our early feasibility study, which has provided rich learnings in the real-world application our THT therapy in humans... We have treated a variety of melanoma tumour types in our first cohort and have encountered no significant adverse health events in patients."
• David Regan, Sona CEO: "We are encouraged by the progress of our first-in-human clinical study and pleased to be progressing toward having validating clinical data that will further complement our existing preclinical data... we are currently working to incorporate the significant learnings to date from our early feasibility study into our application to Health Canada."